Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.04.2023 | Case report

Antineoplastics/AZD-1222

Rash, polyarthritis and worsening of pre-existing rash and polyarthritis: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Pakvisal N, et al. Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls. Human Vaccines and Immunotherapeutics 18: 2094149, No. 6, Jan 2022. Available from: URL: http://www.tandfonline.com/loi/khvi20 Pakvisal N, et al. Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls. Human Vaccines and Immunotherapeutics 18: 2094149, No. 6, Jan 2022. Available from: URL: http://​www.​tandfonline.​com/​loi/​khvi20
Metadaten
Titel
Antineoplastics/AZD-1222
Rash, polyarthritis and worsening of pre-existing rash and polyarthritis: 3 case reports
Publikationsdatum
01.04.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-36836-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Somatropin

Case report

Antineoplastics

Case report

Efavirenz

Case report

Pembrolizumab